Evaluation of disease-free survival as a predictor of overall survival and assessment of real-world burden of disease recurrence in resected early-stage non–small cell …
BACKGROUND: Intermediate endpoints, such as disease-free survival (DFS), have shown
good correlation with overall survival (OS) in early-stage non–small cell lung cancer …
good correlation with overall survival (OS) in early-stage non–small cell lung cancer …
[HTML][HTML] Generating real-world tumor burden endpoints from electronic health record data: comparison of RECIST, radiology-anchored, and clinician-anchored …
SD Griffith, M Tucker, B Bowser, G Calkins, C Chang… - Advances in …, 2019 - Springer
Introduction Real-world evidence derived from electronic health records (EHRs) is
increasingly recognized as a supplement to evidence generated from traditional clinical …
increasingly recognized as a supplement to evidence generated from traditional clinical …
Meta-analysis exploring the effect of oncogenic driver mutations on outcome of metastatic non-small cell lung cancer (mNSCLC) patients (pts) treated with immune …
A Agyeman, JJ Vallejo, A Myers, GM Blumenthal - 2018 - ascopubs.org
9029 Background: Recent reports suggest that pts with mNSCLC with tumor EGFR
mutations (EGFRm) receiving ICI as second line-plus (2L+) therapy may have better clinical …
mutations (EGFRm) receiving ICI as second line-plus (2L+) therapy may have better clinical …
[HTML][HTML] Real-world clinical impact of immune checkpoint inhibitors in patients with advanced/metastatic non–small cell lung cancer after platinum chemotherapy
L Schwartzberg, B Korytowsky, JR Penrod, Y Zhang… - Clinical lung cancer, 2019 - Elsevier
Background The real-world effect of anti-programmed death ligand 1 (PD-L1) therapies is
unclear. We compared US patients who received second-line therapy for non–small-cell …
unclear. We compared US patients who received second-line therapy for non–small-cell …
Real-world healthcare resource utilization in a European non-small cell lung cancer population: the EPICLIN-Lung study
A Vergnenegre, A Carrato, M Thomas… - … medical research and …, 2014 - Taylor & Francis
Background: There is a lack of data on health resource assessment in non-small cell lung
cancer (NSCLC) to inform clinical decision-making. The Epidemiological Study to Describe …
cancer (NSCLC) to inform clinical decision-making. The Epidemiological Study to Describe …
[HTML][HTML] Treatment patterns in stage III non‑small‑cell lung cancer patients: a population‑based study using German cancer registry data
A Bedir, S Mehrotra, J Gnüchtel, D Vordermark… - Journal of Cancer …, 2023 - Springer
Purpose Lung cancer remains the leading cause of cancer-related mortality worldwide,
mostly due to delayed diagnosis. The objective of this study is to examine the treatment …
mostly due to delayed diagnosis. The objective of this study is to examine the treatment …
Adverse event costs associated with first-line therapy for advanced non–small cell lung cancer in the United States: An analysis of clinical trials of immune checkpoint …
BACKGROUND: Immune checkpoint inhibitors, such as pembrolizumab, nivolumab, and
atezolizumab, have demonstrated substantial survival benefits in patients with advanced …
atezolizumab, have demonstrated substantial survival benefits in patients with advanced …
[HTML][HTML] Real-world landscape transition of death causes in the immunotherapy era for metastatic non-small cell lung cancer
Y Wu, Z Yao, J Zhang, C Han, K Kang… - Frontiers in …, 2022 - frontiersin.org
Background With approval of anti-PD-1/PD-L1, metastatic non-small cell lung cancer
(NSCLC) has entered the era of immunotherapy. Since immune-related adverse events …
(NSCLC) has entered the era of immunotherapy. Since immune-related adverse events …
[HTML][HTML] The value of innovation: association between improvements in survival of advanced and metastatic non-small cell lung cancer and targeted and …
S Ramagopalan, TP Leahy, J Ray, S Wilkinson… - BMC medicine, 2021 - Springer
Background Significant improvements in mortality among patients with non-small cell lung
cancer (NSCLC) in the USA over the past two decades have been reported based on …
cancer (NSCLC) in the USA over the past two decades have been reported based on …
Clinical management patterns and treatment outcomes in patients with non-small cell lung cancer (NSCLC) across Europe: EPICLIN-Lung study
A Carrato, A Vergnenègre, M Thomas… - … medical research and …, 2014 - Taylor & Francis
Abstract Background: Throughout Europe, physicians face similar challenges in non-small
cell lung cancer (NSCLC) management, but comprehensive international information on …
cell lung cancer (NSCLC) management, but comprehensive international information on …